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Abstract
Background: Percutaneous radiofrequency ablation (RFA) has gained popularity in the treatment
of hepatocellular carcinoma (HCC). However, its role versus other conventional minimally invasive
therapies is still a matter of debate. The purpose of this work is to analyse the efficacy and safety
of RFA versus that of ethanol injection (PEI), the percutaneous standard approach to treat
nonsurgical HCC.
Methods: Systematic review and meta-analysis of randomised or quasi-randomised controlled
trials published up to August 2008 in PubMed, ISI Web of Science and The Cochrane Library.
Overall survival, local recurrence rate and adverse effects were considered as primary outcomes.
Studies were critically appraised and estimates of effect were calculated according to the random-
effects model. Inconsistency across studies was evaluated using the I2 statistic. Sensitivity analyses
were conducted to explore statistical heterogeneity.
Results: Six studies were eligible. The studies reported data on 396 patients treated by RFA and
391 treated by PEI. In general, subjects were in Child-Pugh class A (74%) and had unresectable HCC
(mean size 2.5 cm). Mean follow-up was 25 ± 11 months. The survival rate showed a significant
benefit for RFA over PEI at one, two, three and four years. The advantage in survival increased with
time with Relative Risk values of: 1.28 (95%CI:1.12–1.45) and 1.24 (95%CI:1.05–1.48) for RFA
versus PEI at 3- and 4-years respectively. Likewise, RFA achieved significantly lower rates of local
recurrence (RR: 0.37, 95%CI: 0.23–0.59). The overall rate of adverse events was higher with RFA
(RR:2.55, 95%CI: 1.8–3.6) yet no significant differences were found concerning major complications
(RR:1.85, 95%CI: 0.68–5.01). There was not enough evidence supporting a better cost-effectiveness
ratio for RFA compared to PEI.
Conclusion: Available evidence from adequate quality controlled studies support the superiority
of RFA versus PEI, in terms of better survival and local control of the disease, for the treatment of
patients with relatively preserved liver function and early-stage non-surgical HCC. However, the
higher rate of adverse events displayed is something that will have to be tested with appropriate
weighting of the possible benefits in each individual case. Overall cost-effectiveness of RFA needs
further evaluation.
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Background
Worldwide, hepatocellular carcinoma (HCC) constitutes
an important problem for healthcare systems due to its
high morbidity, mortality and progressive incidence [1].
HCC is the sixth leading tumour in the world [2], and it is
estimated that its incidence will continue to rise in com-
ing decades [3,4]. It is an aggressive tumour that usually
develops in a cirrhotic liver with limited functional
reserve, and without treatment registers a short survival
after diagnosis [5]. Furthermore, unlike other tumours,
HCC can be offered few possibilities of curative radical
treatment [1]. Indeed, despite the fact that screening sys-
tems have improved the early diagnosis rate [6], the vast
majority of patients are not susceptible to curative treat-
ment when this tumour is detected [7].
Over the past few years, several methods for percutaneous
tumour destruction have been developed [8,9]. Out of
these, radiofrequency ablation (RFA) is the one that has
attracted greatest interest and popularity and, presently, it
is the most widely employed liver-directed treatment of
early-stage non-surgical HCC [10,11]. Indeed, there has
been a drastic shift from standard percutaneous treat-
ments, such as Percutaneous Ethanol Injection (PEI), to
RFA since the introduction of the latter in clinical practice
[12].
Yet, to date, little is known of the efficacy and safety of
percutaneous RFA versus that of other conventional min-
imally invasive loco-regional therapies [12-15], and the
advantages of RFA versus PEI in terms of cardinal out-
comes, such as survival, have not been demonstrated
[1,13,14].
Accordingly, based on a systematic review and meta-anal-
ysis of the literature, this study sought to assess existing
evidence about the efficacy and safety of percutaneous
RFA versus that of PEI in the management of HCC.
Methods
A review of the literature was conducted in PubMed, ISI
Web of Science and The Cochrane Library from January
1990 to August 2008, using the following terms: "carci-
noma, hepatocellular" [MeSH Terms], "radiofrequency
catheter ablation" [MeSH Terms], "ethanol injection"
[Text Word] and "controlled trial" [Publication Type].
Similarly, a manual search of the relevant references was
made and experts were contacted in order to identify pub-
lished studies [15]. Conversely, we did not attempt to con-
tact companies producing RFA equipment.
Inclusion criteria
Sackett's criteria [16], duly amended, were applied as fol-
lows: 1) population: randomised or quasi-randomised
controlled studies conducted on more than 10 adults with
formal diagnosis of HCC; 2) intervention: percutaneous
RFA; 3) comparator: PEI; 4) results: studies were required
to describe data related to at least one of the following pri-
mary variables of efficacy and safety, namely, overall sur-
vival, local recurrence rate and adverse effects. Other
variables such as disease-free survival, complete tumour
response and use of health-care resources were considered
as secondary outcomes.
Since this study's aim was to identify existing evidence on
the efficacy and safety of RFA versus PEI in the treatment
of HCC, no limitations based on duration of follow-up
period were established [15,17].
Selection of studies
The selected studies were examined by two independent
reviewers, with any disagreements being settled by discus-
sion of the respective study data.
Data extraction
Original data were extracted on a standard form that
included: a) details of the study design, inclusion/exclu-
sion criteria and duration of follow-up; b) information on
the study population; c) information on the intervention
and comparator; and lastly, d) information on the out-
come measures of efficacy and safety.
Analysis of methodological quality and scientific evidence
This was conducted in accordance with validated recom-
mendations [18].
Data analysis and synthesis of results
To obtain an overall measure of the efficacy and safety of
RFA versus that of the comparator, standard meta-analyt-
ical techniques were used. Pooled effect was estimated
using a random-effects model [19]. We analysed dichot-
omous variables using estimation of relative risk (RR)
with a 95% confidence interval, and continuous varia-
bles using weighted mean difference (WMD) with a 95%
confidence interval. The degree of inconsistency between
studies was quantified using the I2  statistic which
describes the proportion of variance across studies not
due to chance. I2 <25% and I2 >50% reflect small and
large inconsistency, respectively [20]. Sensitivity analy-
ses were conducted to explore statistical heterogeneity
[21].
In accordance with some recent literature we have not
used funnel plots to examine the possibility of publica-
tion bias, given the limitations and potential misleading
results of these graphs [22].
All analyses were performed using the SE Stata 9 computer
software package (StataCorp LP Texas USA 1984–2005).
Results were deemed significant at a P-value < 0.05.BMC Gastroenterology 2009, 9:31 http://www.biomedcentral.com/1471-230X/9/31
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We used Visual RX Version 3 http://www.nntonline.net to
calculate, where appropriate, the number needed to treat
(NNT) or the number needed to harm (NNH).
Results
As Figure 1 shows, the bibliographic search yielded 241
references. Hand searching of retrieved articles yielded no
additional studies. After excluding references without an
abstract, studies with a non percutaneous RFA technical
approach, studies not reporting outcomes separately from
data on patients with hepatic metastases, and redundan-
cies arising from the use of several databases, a total of
seven publications [23-29] were selected.
As Olschewski's [24] data are included within Lencioni et
al.'s [25] (Table 1), a total of 6 studies, published from
1999 to 2008, finally met the inclusion criteria. The stud-
ies reported data on 396 patients treated by RFA and 391
treated by PEI. In general, subjects had unresectable HCC
without vascular invasion and extrahepatic spread; mean
size was 2.5 cm and 57% (619 of 1084 tumours) were sin-
gle tumours. Most patients (74%) were in Child-Pugh
class A (Table 1). Mean duration of follow-up was 25 ± 11
months. In every study serial assessments including clini-
cal evaluations, analysis of tumour markers and imaging
studies were usually performed during follow-up to assess
the treatment response and to detect tumour recurrence.
Shiina et al. [28] reported that, additionally, when local
recurrence was suspected, a biopsy was performed.
As Table 2 shows, there were no significant differences
between groups as regards Child-Pugh grade of liver dys-
function, tumour size, number of single tumours and
duration of follow-up.
A) Clinical efficacy
Selected studies report data on overall survival over differ-
ent time intervals and only in the first 4 years of treatment
(Table 1). At 1 year, meta-analysis shows a survival rate of
96% (95%CI: 92%–98%) in the RFA and of 91% in the
PEI treated-group with differences being small but statisti-
cally significant in favour of RFA (Table 2). Pooled analy-
ses of the five studies that furnished data on survival at 2
years found an overall survival rate of 86% (95%CI:80%–
90%) in the RFA treated-group (n = 354). Meta-analysis
shows, with large consistency across trials, a significant
difference in favour of RFA (Table 2) being the calculated
NNT of 11 (95%CI:7–23).
Flow diagram for study selection and inclusion Figure 1
Flow diagram for study selection and inclusion.
References identified by search n=241
Abstracts excluded because of design or 
failure to deal with RFA versus PEI, 
n=234.
Potentially relevant references n=7
Studies finally included n=6
Duplications =1BMC Gastroenterology 2009, 9:31 http://www.biomedcentral.com/1471-230X/9/31
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At 3 years, the pooled analysis of the 4 studies furnishing
data shows that 74% (95%CI: 66%–86%) of RFA treated-
patients (n = 302) survived. Furthermore, this analysis
shows, also with a high degree of consistency, that RFA
achieved a significantly higher survival rate than PEI (Table
2, Figure 2) with a calculated NNT of 7 (95%CI:4–15).
Data from the two studies analysing this variable at 4
years indicate 62% survival rate (95%CI: 54%–75%) in
the RFA-treated group. Joint analysis also shows a statisti-
cally significant improvement in survival in this group
compared to PEI (Table 2). The calculated NNT here is 9
(95%CI: 5–40).
Furthermore, pooled analysis of studies furnishing data
found that, at the end of the follow-up period, the rates of
local tumour recurrence were 7% (95%CI: 4%–10%) and
22% (95%CI: 17%–27%) in the RFA and PEI treated-
groups respectively. These differences were found to be
statistically significant (Figure 3, Table 2), with a calcu-
lated NNT of 9 (95%CI: 6–25).
Concerning secondary outcomes, as Table 2 shows, our
results indicate that one, two and three year disease-free
survival rates were significantly higher in the RFA group.
Likewise RFA was accompanied by a significantly higher
rate of radiological complete necrosis. Conversely, no sta-
tistical differences were found as regards remote intra-
hepatic recurrence outside the treated field.
B) Safety
Table 3 lists the complications reported in individual studies.
Overall, complications were described in 19% of patients
(95% CI: 15%–23%) treated by RFA and in 10.5% (95%
CI:7–13.5%) of those treated by PEI, with the difference
Table 1: Percutaneous RFA vs. PEI. Summary of characteristics and quality of included studies.
Author/year of 
publication
Design Inclusion criteria RFA
P, [T]
PEI
P, [T]
Child-Pugh
A/B/C
Mean follow-up
(months/years)
Quality
Livraghi24
1999
quasi-RCT Cirrhosis/chronic hepatitis and HCC 
≤ 3 cm.
42, [52] 44, [60] RFA 39/3/0
PEI 38/6/0
10 m. (4–28) 2Diii
Lencioni26 2003
includes Olschewski25
RCT Cirrhosis, single HCC ≤ 5 cm or 3 
nodules ≥ 3 cm each. HCC at 1 cm 
hepatic hilum or gallbladder. No 
vascular invasion or extrahepatic 
metastasis. Child-Pugh: A or B. No 
previous treatment. No candidate 
for resection-transplantation.
52, [69] 50, [73] RFA 45/7/0
PEI 35/15/0
RFA 22.9 ± 9.4 m.
PEI 22.4 ± 8.6 m.
1iiA
Lin27
2004
RCT Cirrhosis, HCC 1–4 cm maximum. 
Child-Pugh A or B. No previous 
treatment. Tumour site >5 mm from 
the hilum or common bile duct.
52, [64] 52, [56] RFA 41/11/0
PEI 39/12/0
RFA 24.5 ± 1.3 m.
PEI 23.8 ± 10.4 m.
1iiA
Lin28
2005
RCT 1–3 HCC ≤ 3 cm, a minimum of 1 
cm from the hilum and gallbladder, 
no vascular invasion or extrahepatic 
metastasis. Child-Pugh A or B 
cirrhosis. Initial treatment.
62, [78] 62, [76] RFA 46/16/0
PEI 47/15/0
RFA 28 ± 12 m.
PEI 26 ± 13 m.
1iiA
Shiina29
2005
RCT Unresectable HCC or patient's 
refusal of surgery. ≤ 3 lesions ≤ 3 cm. 
Child-Pugh A or B. No extrahepatic 
metastasis or vascular invasion. No 
previous or simultaneous 
malignancy.
118, [187] 114, [192] RFA 85/33/0
PEI 85/29/0
RFA 0.6–4.3 y.
PEI 0.1–4.2 y.
1iiA
Brunello30
2008
RCT Cirrhotic patients in Child-Pugh A or 
B with 1–3 HCC nodes ≤ 3 cm. 
Tumour site ≥ 1 cm from the hilum, 
gallbladder, colon or stomach. No 
venous invasion, no metastatic 
disease. Patients no suitable for 
resection or liver transplantation.
70, [89] 69, [88] RFA 39/31/0
PEI 39/30/0
RFA 26.1 m.
PEI 25.3 m.
1iiA
RCT: randomised controlled trial. RFA: Percutaneous radiofrequency ablation. PEI: Percutaneous ethanol injection; P: patients; T: tumours.
Quality of studies: all based on reference 19.BMC Gastroenterology 2009, 9:31 http://www.biomedcentral.com/1471-230X/9/31
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Table 2: P-RFA vs. PEI: Results of meta-analysis
Variables No. of studies furnishing data Results RR/WMD (95% CI) P-value I2
RFA PEI
Baseline characteristics:
Child-Pugh grade of liver dysfunction
A
B
624,26–30
624,26–30
71%
24%
70%
26%
1.05 (0.97, 1.13), 0.44
0.92 (0.74, 1.15), 0.43
0%
0%
Tumour size, cm (mean ± SEM) 426–28,30 2.62 ± 0.33 2.47 ± 0.35 0.13 (0.01, 0.25),0.03 0%
Single nodule 624,26–30 59% 55% 1.04 (0.94, 1.50), 0.44 17%
Follow-up duration, months 
(mean ± SEM)
326–28 25 ± 6.2 23.6 ± 5.6 0.97 (-1.32, 3.3), 0.4 0%
Efficacy:
Survival
1 year
2 years
3 years
4 years
526–30
526–30
427–30
229,30
96%
86%
73%
62%
91%
75%
58%
51%
1.04 (1.007, 1.08), 0.02
1.13 (1.06, 1.20), <0.001
1.28 (1.12, 1.45), <0.001
1.24 (1.05,1.48), <0.001
0%
0%
12.6%
0%
Local recurrence 426–29 7% 22% 0.37 (0.23, 0.59), 0.000 0%
Disease-free survival
1 year
2 years
3 years
326–28
326–28
227,28
80%
61%
40%
70%
42%
19%
1.13 (1, 1.28), 0.04
1.31 (1.06, 1.61), 0.013
2.1 (1.35, 3.23), 0.001
0%
0%
0%
Tumour complete response 424,26–28 93.5% 84.5% 1.10 (1.04, 1.17), 0.01 0%
Remote intra-hepatic recurrence 526–30 43% 45% 0.97 (0.82, 1.11), 0.56 0%
Safety:
Total complications 624,26–30 19.2% 10.5% 2.55 (1.8, 3.65), <0.001 0%
Major complications 424,28–30 4.1% 2.7% 1.85 (0.68, 5.01); 0.22 0%
RR: Relative risk. WMD: Weighted mean difference. All based on random effects meta-analysis.
RFA vs. PEI: Results of the meta-analysis on overall survival at 3 years Figure 2
RFA vs. PEI: Results of the meta-analysis on overall survival at 3 years. CI: Confidence interval. All based on a ran-
dom-effects meta-analysis.BMC Gastroenterology 2009, 9:31 http://www.biomedcentral.com/1471-230X/9/31
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RFA vs. PEI: Results of the meta-analysis on local recurrence rate Figure 3
RFA vs. PEI: Results of the meta-analysis on local recurrence rate. CI: Confidence interval. All based on a random-
effects meta-analysis.
Table 3: RFA vs. PEI. Summary of complications described in individual studies
Type RFA (number of cases) PEI (number of cases)
Severe pain 27 14
Fever 10 5
Haemothorax 4
Pneumothorax 1
Pleural effusion 7
Gastric perforation 1
Cholecystitis 1
Intraperitoneal bleeding 2 1
Haemobilia 1
Hepatic infarction 1
Subcapsular haematoma 5 1
Transitory icterus 1
Ascitis 1 2
Acute cholangitis 1
Hepatic abscess 1
Portal vein thrombosis 2 9
Biliary stricture 1
Hypertransaminaemia 3 1
Thermal burn to colon 1
Cutaneous burn 1 2
A-V shunt 3
Neoplastic cell seeding 3 1
Psychotic reaction 1
Vagal reaction 1
Procedure-related death 1BMC Gastroenterology 2009, 9:31 http://www.biomedcentral.com/1471-230X/9/31
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being statistically significant and favourable to PEI (Table 2)
and an estimated NNH of 7 (95%CI:4–13) with RFA.
Only four studies report on complications defined as
being major by the respective authors. The rate of major
complications in the RFA treated-patients was 4.1%
(95%CI: 1.8%–6.4%) and include: haemotorax requiring
thoracostomy drainage, gastric bleed, haemoperitoneum,
transitory icterus, liver infarction, cutaneous burn and
tumoral cell seeding. In the PEI-group, 2.7% (95%CI:
0.4%–5.1%) of patients had major complications includ-
ing: liver abscess, haemoperitoneum, tumoral cell seeding
and one procedure-related death. Pooled analysis of these
major complications, showed that, despite there being a
trend towards a greater number in the RFA group, this dif-
ference failed to reach statistical significance (Table 2).
C) Use of resources
Joint analysis of four studies [25-28] indicates that the
number of sessions per tumour treated was significantly
lower in the case of RFA (WMD: -4.26, (-4.8, -3.7),
<0.001; I2:88%). When potential reasons for heterogene-
ity were explored, the studies varied in terms of both clin-
ical variables and methodological quality. However, a
range of sensitivity analysis showed no appreciable differ-
ences between the pooled-effect sizes obtained.
Three studies [26-28] furnished combinable data on mean
hospital stay. In two of these, hospital stay was longer in the
RFA-treated group, whilst Shiina et al. report data on very
prolonged stays in the PEI-treated group, without citing the
causes. Although combined analysis showed no significant
differences [WMD: -2.91 (-7.91, 2.08), P = 0.2], inconsist-
ency across studies was very pronounced (I2:99%), render-
ing interpretation of results difficult.
Only Brunello et al. [29] conducted a formal evaluation of
hospital costs. These authors found that the mean direct
medical costs were 4097 for patients in the PEI group and
6540 for those in the RFA group (p < 0.001). In addition,
they estimated an incremental health-care cost of 8286
(95%CI: 2742–20 917 ) for each additional patient suc-
cessfully treated by RFA.
Discussion
The results of this meta-analysis indicate that RFA is supe-
rior to PEI in terms of overall survival and lower local
recurrence rates for patients with Child-Pugh class A or B
cirrhosis and an early nonsurgical HCC. However, the
higher rate of adverse events displayed is something that
will have to be tested with appropriate weighting of the
possible benefits in each individual case.
While according to recent guidelines PEI should be con-
sidered the standard technique for percutaneous treat-
ment of HCC in patients with cirrhosis [30], RFA has
emerged as a real competitor to PEI in clinical grounds
and is currently used as the primary ablative modality at
most institutions [31,32]. However, to date, the survival
benefit of RFA versus that of PEI for HCC is controversial
[1,13,14,31].
In this study, a significant benefit in RFA vs. PEI in overall
survival was observed. Interestingly enough, though indi-
vidual studies provide data only in the first 4 years of treat-
ment, the advantage in survival increases with time.
Indeed at 3 years there is a 28% higher survival rate for the
RFA-treated group with a calculated NNT of 7. From a
clinical point of view these findings seem to be highly sig-
nificant, and although the number of studies furnishing
combinable data is limited, the absence of patent differ-
ences between groups with regards to Child-Pugh grade of
liver dysfunction, tumour size or number of single
tumours, highlights the possible benefits of RFA itself.
Furthermore it is important to emphasize the high degree
of consistency found across studies and their methodolog-
ical quality, something that increases the strength of these
results. In addition, the rates of survival found in the PEI
group, while somewhat lower, are comparable to that
reported in prior studies conducted in patients with HCC
of similar characteristics [33,34].
The improvement observed regarding survival can be
explained by the fact that, as this study confirms, RFA is
superior to PEI in achieving local control of the disease as
demonstrated by its greater disease-free survival rates,
complete radiological tumour response, and its signifi-
cantly lower local recurrence rates [31,35-38]. Concerning
this cardinal variable, our data show, with enormous con-
sistency across the combinable studies, that RFA has a
63% lesser risk of local recurrence than PEI with a calcu-
lated NNT of 9 (95%CI: 6–25). Conversely, and as
expected because it is not influenced by local treatment,
no significant differences were found concerning remote
hepatic recurrence rates outside the treated field [38].
Insofar as safety is concerned, though data are limited,
available evidence indicate that, whereas there are no sig-
nificant differences between the two techniques in the
case of major complications, RFA displays an overall com-
plication rate which is significantly higher than that
observed with PEI, with a calculated NNH of about 7.
The overall rate of complications was 19% in the RFA
treated-group, which is clearly higher than the 7% previ-
ously reported for this percutaneous approach [39]. On
the other hand, we should point out that the rate of major
complications found in this study (4%) is rather compa-
rable to recently published data [40]. While these rates do
not translate into an increase in mortality they have to be
taken into account, especially because this procedure has
rapidly evolved into the most popular percutaneous ther-BMC Gastroenterology 2009, 9:31 http://www.biomedcentral.com/1471-230X/9/31
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apy for HCC in clinical settings. Here, we must point out
that some of the complications observed could be due to
the effect of the learning curve [41] and professionals' dif-
fering degree of experience [42] in RFA.
Lastly, RFA seems superior to PEI in terms of some health-
resource-related variables, such as number of sessions per
tumour treated and mean hospital stay. In contrast, in the
cost-effectiveness analysis made by Brunello et al. [29],
RFA was found to be more expensive than PEI with mean
direct costs showing a significant positive difference not
balanced by a better impact on the overall survival rate.
Consequently, to date there is no evidence supporting a
better cost-effectiveness ratio for RFA from a social per-
spective. In addition, it is important to recognise the diffi-
culties in comparing the length of hospital stay and the
costs of RFA versus PEI among studies of diverse setting
due, in part, to the difference in resource use and patterns
of care between different countries. These differences also
hinder direct comparisons and extrapolation of the results
to different communities.
Potential report limitations
It has to be recognised that publication bias is possible
and that, by not including unpublished studies, the effi-
cacy and safety of RFA versus PEI may not have been fully
adequately estimated. Nevertheless, we feel that any such
bias would necessarily have been minimised by the scope
of and systematic strategy used in the search of the litera-
ture and we are confident that the majority of the research
conducted in this field was successfully identified [15,43].
However, in line with prior reports, we decided not to
include unpublished data from industry given both the
difficulties encountered in obtaining this information and
the recognition that the use of these data may not neces-
sarily reduce the bias in meta-analysis [43,44].
We should, moreover, stress the fact that, in this study, a
number of accredited methods were used to reduce possi-
ble biases (extensive search of the literature; duplicate
data-extraction; use of explicit criteria for both methodo-
logical assessment and analysis; and use of a random-
effects model for effect estimation). Additionally, cardinal
clinical results as overall survival were analysed [45].
Lastly, this study highlights the presence of several limita-
tions in the papers located in the literature among which
the cursory description of results and the absence of strat-
ification according to recognised prognostic parameters
with regards to both tumour size and hepatic functional
reserve, reduce the possibility of the applications and clin-
ical limitations of RFA being identified more accurately.
In this regard, it has to be recognised that although the
efficacy of RFA is known to be size dependent [36], no
subgroup analysis based on tumour size could be carried
out given the absence of adequate information on this
respect in the individual studies. Similarly, there is an evi-
dent lack of long-term data on patient survival. Most of
the studies had follow-up periods of approximately 2–3
years and there are no consistent data on longer follow-
ups. There is no doubt that this is a limitation which will
be overcome in the future, rendering it possible for patient
prognoses to be correctly evaluated.
Conclusion
Despite limitations, available evidence from adequate
quality controlled studies support the superiority of RFA
versus PEI in terms of better survival and local control of
the disease for the treatment of patients with relatively
preserved liver function and early-stage non-surgical
HCC. However, the higher rate of adverse events dis-
played is something that will have to be tested with appro-
priate weighting of the possible benefits in each
individual case. Overall cost-effectiveness of RFA needs
further evaluation.
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